Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | UBE2M | P61081 | 1/20 | 0.30 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3327809 | 0.86 | KCNH2 (0.45) | KCNH2 | |
| SCHEMBL3327813 | 0.86 | KCNH2 (0.45) | KCNH2 | |
| SCHEMBL3153679 | 0.80 | KCNH2 (0.33) | KCNH2 | |
| SCHEMBL3146460 | 0.80 | L3MBTL1 (0.37) | SLC2A1KCNH2 | |
| SCHEMBL3331892 | 0.79 | KCNH2 (0.37) | HSD11B1KCNH2 | |
| SCHEMBL3331050 | 0.77 | KCNH2 (0.35) | HSD11B1KCNH2 | |
| SCHEMBL3149416 | 0.76 | SLC2A1 (0.51) | SLC2A1KCNH2 | |
| SCHEMBL3326917 | 0.76 | KCNH2 (0.56) | KCNH2 | |
| SCHEMBL3325759 | 0.75 | KCNH2 (0.34) | KCNH2 | |
| SCHEMBL705916 | 0.74 | OPRM1 (0.36) | UBE2MDCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137353-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2010-06-03 | — | — | US | disclosed |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | GLAXO GROUP LIMITED (GB) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137353-A1 | TRICYCLIC COMPOUNDS AS ANTIBACTERIALS | NRDC, NACA, NOP2 | HSD11B1 4493/4885SLC2A1 4498/4885KCNH2 2974/4885 |
| US-20100048544-A1 | PYRROLO (3, 2, 1-IJ) QUINOLINE-4-ONE-DERIVATIVES FOR TREATING TUBERCULOSIS | NQO2, MT-ND1, SDHB | HSD11B1 1341/4885SLC2A1 4630/4885KCNH2 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.